[HTML][HTML] Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors
MG Ferrara, L Belluomini, A Smimmo, M Sposito… - Critical Reviews in …, 2023 - Elsevier
Purpose To assess the prognostic impact of TP53 mutations in EGFR-mutant advanced
NSCLC patients treated with TKIs. Methods Studies exploring the clinical outcomes of EGFR …
NSCLC patients treated with TKIs. Methods Studies exploring the clinical outcomes of EGFR …
Prevalence of oncogenic driver mutations in Hispanics/Latin patients with lung cancer. A systematic review and meta-analysis
Introduction The frequency of actionable mutations varies between races, and
Hispanic/Latino (H/L) people are a population with different proportions of ancestry. Our …
Hispanic/Latino (H/L) people are a population with different proportions of ancestry. Our …
Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged NSCLC
L Lara-Mejía, AF Cardona, L Mas, C Martin… - Journal of Thoracic …, 2024 - Elsevier
Introduction ALK tyrosine kinase inhibitors have exhibited promising activity against
advanced ALK-rearranged NSCLC. However, co-occurring genetic alterations, such as …
advanced ALK-rearranged NSCLC. However, co-occurring genetic alterations, such as …
NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR‐mutated NSCLC: translational research of …
S Ikeda, M Tsuboi, K Sakai, T Misumi… - Molecular …, 2024 - Wiley Online Library
The phase III IMPACT study (UMIN000044738) compared adjuvant gefitinib with cisplatin
plus vinorelbine (cis/vin) in completely resected epidermal growth factor receptor (EGFR) …
plus vinorelbine (cis/vin) in completely resected epidermal growth factor receptor (EGFR) …
Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case series
P Christopoulos, F Herster, P Hoffknecht, M Falk… - Frontiers in …, 2024 - frontiersin.org
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent first-line
standard of care in unresectable EGFR mutation-positive (EGFRm+) non-small cell lung …
standard of care in unresectable EGFR mutation-positive (EGFRm+) non-small cell lung …
Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic …
R Motta-Guerrero, A Leon Garrido-Lecca… - Frontiers in …, 2024 - frontiersin.org
Background The EGFR gene encodes a protein that stimulates molecular pathways that
allow the growth and development of the tumor microenvironment. The current preferred …
allow the growth and development of the tumor microenvironment. The current preferred …
Concomitant genomic features stratify prognosis to patients with advanced EGFR mutant lung cancer
X Liang, J Xu, Y Jiang, Y Yan, H Wu, J Dai… - Molecular … - Wiley Online Library
This study aimed to explore the clinical significance of genomics features including tumor
mutation burden (TMB) and copy number alteration (CNA) for advanced EGFR mutant lung …
mutation burden (TMB) and copy number alteration (CNA) for advanced EGFR mutant lung …
Alteraciones genómicas concurrentes en pacientes con cáncer de pulmón de células no pequeñas con mutación de EGFR
RA Reyna de la Garza - 2023 - eprints.uanl.mx
El cáncer de pulmón es la primera causa de muerte por cáncer a nivel mundial y la segunda
neoplasia más diagnosticada. El cáncer de pulmón de células no pequeñas (CPCNP) es el …
neoplasia más diagnosticada. El cáncer de pulmón de células no pequeñas (CPCNP) es el …
[HTML][HTML] Treatment sequences in EGFR mutant advanced NSCLC
M Wespiser, A Swalduz, M Pérol - Lung Cancer, 2024 - Elsevier
Common EGFR gene mutations (exon 19 deletion and L858R in exon 21) are the most
frequent cause of actionable genomic alterations in non-small cell lung cancer (NSCLC) …
frequent cause of actionable genomic alterations in non-small cell lung cancer (NSCLC) …